MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

YY Janjigian, E Van Cutsem, K Muro, Z Wainberg… - Future …, 2022 - Taylor & Francis
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …
被引用次数：69 相关文章

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.

YY Janjigian, E Van Cutsem, K Muro… - Future Oncology …, 2022 - europepmc.org
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

YY Janjigian, E Van Cutsem, K Muro… - Future oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

YY Janjigian, E Van Cutsem, K Muro… - Future …, 2022 - yonsei.elsevierpure.com
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

YY Janjigian, E Van Cutsem, K Muro, Z Wainberg… - 2022 - ir.ymlib.yonsei.ac.kr
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

YY Janjigian, E Van Cutsem, K Muro, Z Wainberg… - Future Oncology, 2022 - cir.nii.ac.jp
抄録< jats: p> Standard-of-care for resectable gastric/gastroesophageal junction cancer
includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel …
[PDF] kuleuven.be

[PDF][PDF] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

WJH Al-Batran, D Molena, M Marcovitz, D Ruscica… - Future …, 2022 - lirias.kuleuven.be
Design Study design MATTERHORN is a randomized, double-blind, placebo-controlled,
multicenter, global phase III study to assess the efficacy and safety of neoadjuvant-adjuvant …